Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Financing Activities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Cash from Financing Activities for 12 consecutive years, with $54.9 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 48.66% to $54.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $400.2 million through Dec 2025, up 42.12% year-over-year, with the annual reading at $400.2 million for FY2025, 42.12% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $54.9 million at ImmunityBio, down from $173.5 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $326.0 million in Q4 2021, with the low at -$982000.0 in Q1 2025.
  • Average Cash from Financing Activities over 5 years is $99.0 million, with a median of $87.6 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities soared 289513.33% in 2023, then plummeted 109.6% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $326.0 million in 2021, then tumbled by 66.27% to $109.9 million in 2022, then soared by 82.41% to $200.5 million in 2023, then tumbled by 46.68% to $106.9 million in 2024, then crashed by 48.66% to $54.9 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $54.9 million, $173.5 million, and $172.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.